Genmab AS (Denmark) Price Patterns
| GMAB Stock | DKK 1,766 101.50 5.44% |
Momentum 45
Impartial
Oversold | Overbought |
Using Genmab AS hype-based prediction, you can estimate the value of Genmab AS from the perspective of Genmab AS response to recently generated media hype and the effects of current headlines on its competitors.
The fear of missing out, i.e., FOMO, can cause potential investors in Genmab AS to buy its stock at a price that has no basis in reality. In that case, they are not buying Genmab because the equity is a good investment, but because they need to do something to avoid the feeling of missing out. On the other hand, investors will often sell stocks at prices well below their value during bear markets because they need to stop feeling the pain of losing money.
Genmab AS after-hype prediction price | DKK 1766.0 |
There is no one specific way to measure market sentiment using hype analysis or a similar predictive technique. This prediction method should be used in combination with more fundamental and traditional techniques such as stock price forecasting, technical analysis, analysts consensus, earnings estimates, and various momentum models.
Genmab |
Genmab AS After-Hype Price Density Analysis
As far as predicting the price of Genmab AS at your current risk attitude, this probability distribution graph shows the chance that the prediction will fall between or within a specific range. We use this chart to confirm that your returns on investing in Genmab AS or, for that matter, your successful expectations of its future price, cannot be replicated consistently. Please note, a large amount of money has been lost over the years by many investors who confused the symmetrical distributions of Stock prices, such as prices of Genmab AS, with the unreliable approximations that try to describe financial returns.
Next price density |
| Expected price to next headline |
Genmab AS Estimiated After-Hype Price Volatility
In the context of predicting Genmab AS's stock value on the day after the next significant headline, we show statistically significant boundaries of downside and upside scenarios based on Genmab AS's historical news coverage. Genmab AS's after-hype downside and upside margins for the prediction period are 1,763 and 1,769, respectively. We have considered Genmab AS's daily market price in relation to the headlines to evaluate this method's predictive performance. Remember, however, there is no scientific proof or empirical evidence that news-based prediction models compare with traditional linear, nonlinear models or artificial intelligence models to provide accurate predictions consistently.
Current Value
Genmab AS is very steady at this time. Analysis and calculation of next after-hype price of Genmab AS is based on 3 months time horizon.
Genmab AS Stock Price Outlook Analysis
Have you ever been surprised when a price of a Company such as Genmab AS is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Genmab AS backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Stock price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with Genmab AS, there might be something going there, and it might present an excellent short sale opportunity.
| Expected Return | Period Volatility | Hype Elasticity | Related Elasticity | News Density | Related Density | Expected Hype |
0.23 | 2.59 | 0.00 | 0.00 | 0 Events / Month | 0 Events / Month | In a few days |
| Latest traded price | Expected after-news price | Potential return on next major news | Average after-hype volatility | |
1,766 | 1,766 | 0.00 |
|
Genmab AS Hype Timeline
Genmab AS is currently traded for 1,766on Copenhagen Exchange of Denmark. The entity stock is not elastic to its hype. The average elasticity to hype of competition is 0.0. Genmab is estimated not to react to the next headline, with the price staying at about the same level, and average media hype impact volatility is insignificant. The immediate return on the next news is estimated to be very small, whereas the daily expected return is currently at -0.23%. %. The volatility of related hype on Genmab AS is about 0.0%, with the expected price after the next announcement by competition of 1,766. About 50.0% of the company shares are owned by institutional investors. The company has Price/Earnings To Growth (PEG) ratio of 1.19. Genmab AS recorded earning per share (EPS) of 83.21. The entity had not issued any dividends in recent years. Assuming the 90 days trading horizon the next estimated press release will be in a few days. Check out Genmab AS Basic Forecasting Models to cross-verify your projections. To learn how to invest in Genmab Stock, please use our How to Invest in Genmab AS guide.Genmab AS Related Hype Analysis
Having access to credible news sources related to Genmab AS's direct competition is more important than ever and may enhance your ability to predict Genmab AS's future price movements. Getting to know how Genmab AS's peers react to changing market sentiment, related social signals, and mainstream news is a great way to find investing opportunities and time the market. The summary table below summarizes the essential lagging indicators that can help you analyze how Genmab AS may potentially react to the hype associated with one of its peers.
| HypeElasticity | NewsDensity | SemiDeviation | InformationRatio | PotentialUpside | ValueAt Risk | MaximumDrawdown | |||
| COLO-B | Coloplast AS | 0.00 | 0 per month | 0.00 | (0.18) | 2.27 | (3.34) | 11.82 | |
| BAVA | Bavarian Nordic | 0.00 | 0 per month | 1.47 | (0.02) | 2.38 | (2.89) | 7.11 | |
| ZEAL | Zealand Pharma AS | 0.00 | 0 per month | 0.00 | (0.24) | 3.00 | (4.16) | 13.04 | |
| ALK-B | ALK Abell AS | 0.00 | 0 per month | 0.00 | (0.08) | 2.20 | (2.45) | 6.29 | |
| HLUN-B | H Lundbeck AS | 0.00 | 0 per month | 0.00 | (0.10) | 2.78 | (4.74) | 12.30 | |
| GUBRA | Gubra AS | 0.00 | 0 per month | 0.00 | (0.09) | 4.60 | (6.37) | 16.21 | |
| DEMANT | Demant AS | 0.00 | 0 per month | 0.00 | (0.10) | 3.61 | (3.77) | 14.36 | |
| PEG | Pharma Equity Group | 0.00 | 0 per month | 0.00 | (0.03) | 10.00 | (9.09) | 28.68 | |
| GN | GN Store Nord | 0.00 | 0 per month | 0.00 | (0.04) | 5.21 | (4.15) | 19.43 |
Genmab AS Additional Predictive Modules
Most predictive techniques to examine Genmab price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for Genmab using various technical indicators. When you analyze Genmab charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
About Genmab AS Predictive Indicators
The successful prediction of Genmab AS stock price could yield a significant profit to investors. But is it possible? The efficient-market hypothesis suggests that all published stock prices of traded companies, such as Genmab AS, already reflect all publicly available information. This academic statement is a fundamental principle of many financial and investing theories used today. However, the typical investor usually disagrees with a 'textbook' version of this hypothesis and continually tries to find mispriced stocks to increase returns. We use internally-developed statistical techniques to arrive at the intrinsic value of Genmab AS based on analysis of Genmab AS hews, social hype, general headline patterns, and widely used predictive technical indicators.
We also calculate exposure to Genmab AS's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Genmab AS's related companies.
Pair Trading with Genmab AS
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Genmab AS position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Genmab AS will appreciate offsetting losses from the drop in the long position's value.Moving together with Genmab Stock
Moving against Genmab Stock
| 0.76 | JYIDKAKT | Jyske Invest Danske | PairCorr |
| 0.74 | CARL-B | Carlsberg AS | PairCorr |
| 0.74 | BIV55 | BankInvest Optima | PairCorr |
| 0.74 | BIV75 | BankInvest Optima | PairCorr |
| 0.73 | SYVFVOAKKA | Sydinv Formue Vkstori | PairCorr |
| 0.71 | ORSTED | Orsted AS | PairCorr |
The ability to find closely correlated positions to Genmab AS could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Genmab AS when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Genmab AS - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Genmab AS to buy it.
The correlation of Genmab AS is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Genmab AS moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Genmab AS moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Genmab AS can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Information and Resources on Investing in Genmab Stock
When determining whether Genmab AS offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Genmab AS's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Genmab As Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Genmab As Stock:Check out Genmab AS Basic Forecasting Models to cross-verify your projections. To learn how to invest in Genmab Stock, please use our How to Invest in Genmab AS guide.You can also try the Sectors module to list of equity sectors categorizing publicly traded companies based on their primary business activities.